Neutralising SARS-CoV-2 with intranasally-delivered antibodies

A monoclonal antibody (mAb) developed by IGM Biosciences to combat COVID-19 has shown success in pre-clinical studies and has now moved into Phase I trials. In this Q&A, Dr Chris Takimoto, Chief Medical Officer at IGM Biosciences, explains how this biotherapeutic works to prevent and treat SARS-CoV-2 infection.

While there have been many efforts to develop therapeutics that can protect against SARS-CoV-2 and treat patients following infection, the emergence of variants requires constant review of the options available. A range of mAbs have been used to tackle COVID-19 throughout the pandemic, so ensuring that they are effective at neutralising variants of concern and variants of interest is essential.

IGM-6268, an anti-SARS-CoV-2 immunoglobulin M (IgM) mAb developed by IGM Biosciences for the treatment and prevention of COVID-19, has shown success in this area and is now entering into two Phase I clinical trials.